~~<i id='1174E8E017'><strike id='1174E8E017'><tt id='1174E8E017'><pre id='1174E8E017'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：hotspot 2025-10-02 22:25:02 - browse：9865

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Resistance to opioid

knowledge

leisure time

explore

knowledge

focus

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Astellas still sees hope in its gene therapy after four deaths

Having children helps parents live longer, especially after age 80

Resistance to opioid

Weight loss drug costs may need more research, senator suggests

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

explore

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

PBM reforms clear House panel

As demand for Covid shots wanes, Moderna seeks its next success

Abbott's new heart device gets FDA advisory panel nod

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

World's first CRISPR

Heart attack and stroke risk calculators need revising

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Hepatitis C has a cure — but many Americans still lack access to it

David Sabatini, ex

knowledge

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Does good food count as health care? Study aims to find out

Congress must protect the remaining independent doctors

FDA's Woodcock to retire early next year

Astellas still sees hope in its gene therapy after four deaths

leisure time

explore

knowledge

focus